Text Size
37 studies found for:    " April 15, 2009":" May 15, 2009"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]

Modify this search | How to Use Search Results

Show Display Options
Download search resultsDownload the search results for:
" April 15, 2009":" May 15, 2009"[FIRST-RECEIVED-DATE]AND HIV[CONDITION] (37 records)
Need help? See Downloading Content for Analysis
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Completed
Has Results 		A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected Patients
Conditions: HIV Infection;   HIV;   Acquired Immunodeficiency Syndrome
Interventions: Drug: etravirine (ETR, TMC125);   Drug: efavirenz (EFV)
2 Completed Empowerment Intervention for Young Women - Phase I
Conditions: HIV;   Empowerment;   HIV Infections
Intervention: Behavioral: Prevention Empowerment Intervention for Young Women
3 Completed HIV- Risk Reduction Behavioral Intervention for Commercial Sex Workers in Yerevan Armenia
Conditions: HIV Prevention;   HIV Infections
Intervention: Behavioral: HIV risk reduction intervention
4 Completed Linkage to Care - Part II
Conditions: HIV;   Care-seeking;   HIV Infections
Interventions: Other: Case Management;   Other: Snowball sampling;   Other: Referral Lists
5 Completed TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients
Conditions: HIV Infections;   Acquired Immunodeficiency Syndrome
Interventions: Drug: 48 weeks ATV/rtv 300/100mg once daily + ETR 200mg twice daily;   Drug: TDF 300mg;   Drug: ATV/rtv 400/100mg;   Drug: ATV/rtv 300/100mg
6 Completed Efficacy and Safety of Single Versus Double Ritonavir-Boosted Protease Inhibitor (PI)-Based Antiretroviral Therapy (ART) Regimens
Conditions: HIV Infection;   HIV Infections
Interventions: Drug: ritonavir-boosted PI-based second line treatments;   Drug: two PIs boosted by low dose ritonavir or one PI plus full dose ritonavir
7 Active, not recruiting Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Acute Undifferentiated Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Grade III Lymphomatoid Granulomatosis;   Adult Langerhans Cell Histiocytosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Aggressive NK-cell Leukemia;   AIDS-related Diffuse Large Cell Lymphoma;   AIDS-related Diffuse Mixed Cell Lymphoma;   AIDS-related Diffuse Small Cleaved Cell Lymphoma;   AIDS-related Immunoblastic Large Cell Lymphoma;   AIDS-related Lymphoblastic Lymphoma;   AIDS-related Malignancies;   AIDS-related Small Noncleaved Cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Clear Cell Renal Cell Carcinoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Essential Thrombocythemia;   Extramedullary Plasmacytoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   HIV Infection;   HIV-associated Hodgkin Lymphoma;   Intraocular Lymphoma;   Isolated Plasmacytoma of Bone;   Light Chain Deposition Disease;   Mast Cell Leukemia;   Myelodysplastic Syndrome With Isolated Del(5q);   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Myeloid/NK-cell Acute Leukemia;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Osteolytic Lesions of Multiple Myeloma;   Peripheral T-cell Lymphoma;   Plasma Cell Neoplasm;   Polycythemia Vera;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Primary Systemic Amyloidosis;   Progressive Hairy Cell Leukemia, Initial Treatment;   Prolymphocytic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Renal Cell Cancer;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Stage IV Renal Cell Cancer;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Unspecified Adult Solid Tumor, Protocol Specific;   Waldenström Macroglobulinemia
Interventions: Drug: sunitinib malate;   Other: pharmacological study;   Other: laboratory biomarker analysis
8 Completed Safety and Immunogenicity Study of tgAAC09, an HIV Vaccine in an Adeno-associated Virus (AAV) Capsid
Conditions: Human Immunodeficiency Virus Infections;   HIV Infections
Interventions: Biological: tgAAC09;   Other: Formulation buffer
9 Active, not recruiting Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy
Conditions: HIV;   Hyperlipidemia;   Hypertriglyceridemia;   HIV Infections
Intervention: Drug: raltegravir
10 Unknown † Cognitive and Psychosocial Benefits of MISC Training for Ugandan Children
Conditions: HIV;   HIV Infections
Intervention: Behavioral: MISC training for primary caregivers
11 Completed Maraviroc in Immunological Non-Responder (INR) HIV-1-infected Subjects
Condition: HIV Infections
Intervention: Drug: Maraviroc
12 Completed Dose Reduction of Lopinavir in Children
Condition: HIV Infections
Interventions: Drug: Lopinavir/ritonavir standard dose According to WHO simplified dosing table;   Drug: Lopinavir/ritonavir low dose ( 70% of WHO recommended dosing table)
13 Recruiting High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals
Conditions: Cryptococcal Meningitis;   HIV Infections
Interventions: Drug: Fluconazole;   Drug: Amphotericin B
14 Completed TMC207-TiDP13-C117: Interaction Study in Human Immunodeficiency Virus-type 1 (HIV-1) Infected Patients With Nevirapine (NVP)
Condition: HIV Infections
Intervention: Drug: TMC207; nevirapine
15 Active, not recruiting Prevalence and Predictors of Neurocognitive Impairment Among HIV-infected Patients
Conditions: HIV Infections;   Memory
Intervention:
16 Completed Safety and Immunogenicity of TBC-M4, a MVA HIV Vaccine Alone or in a Prime-Boost Regimen With ADVAX DNA HIV Vaccine
Condition: HIV Infections
Interventions: Biological: ADVAX;   Biological: TBC-M4;   Other: Placebo
17 Unknown † Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection
Condition: HIV Infections
Interventions: Drug: Truvada (tenofovir/emitricitabine);   Drug: Kaletra (lopinavir/ritonavir)
18 Completed
Has Results 		Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut
Condition: HIV Infections
Interventions: Drug: raltegravir;   Drug: Study NNRTI;   Drug: Study PI
19 Unknown † Darunavir/Ritonavir and Rosuvastatin Pharmacokinetic Study
Condition: HIV Infections
Interventions: Drug: darunavir, ritonavir, rosuvastatin;   Drug: rosuvastatin, darunavir, ritonavir
20 Active, not recruiting HIV and Kidney Function Study
Conditions: HIV Infections;   AIDS
Intervention:
To Top

Previous Page Studies Shown (1-20) Next Page (21-37) Show next page of results
† Indicates status has not been verified in more than two years